EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis and biological evaluation of 2-phenylquinoxaline carbonyl piperazine derivatives as novel FASN inhibitors with anticancer activity

Shailendra Singh, Subarno Paul, Fábio G Martins, Sérgio F Sousa, Chanakya N Kundu, Chandrabose Karthikeyan, N S Hari Narayana Moorthy

Bioorganic Chemistry · 2025

DOI: 10.1016/j.bioorg.2025.108697 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Shailendra Singh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancept Therapeutics Laboratory, Department of Pharmacy, Indira Gandhi National Tribal University, Lalpur, Amarkantak, Madhya Pradesh 484887, India; …. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Design, Enzyme Inhibitors, Fatty Acid Synthase, Type I. Die Arbeit nennt 31 Literaturangaben. Gefördert von: India Ministry of Science & Technology Department of Science and Technology, Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overexpression of fatty acid synthase (FASN) has been linked to the advancement of various cancers. FASN caters to the increased demand for lipids within tumor cells, facilitating tumor growth and progression, making it an attractive target for anticancer drug discovery. Herein we report a novel series of 2-phenylquinoxaline-6-carboxylic acid derivatives as novel potent FASN inhibitors with anticancer potential. Structure-activity relationship analysis demonstrated that all the synthesized compounds showed potent and selective cytotoxicity against the three cancer cell lines evaluated with IC50 values less than 10 μM. QNX-10 was identified as a promising lead molecule as it elicited potent FASN inhibition and selective cytotoxicity against the colorectal (HCT-116, Caco-2 cell lines) and breast cancer (MCF-7 cell line). Notably, QNX-10 induces apoptosis and cell cycle arrest at S-phase in HCT-116 cells in a dose-dependent manner. Western blot analysis indicated that QNX-10 inhibits FASN and promotes apoptosis in HCT-116 cells by upregulating pro-apoptotic protein Bax and downregulating anti-apoptotic protein Bcl-xL. Molecular docking and MD simulation studies with QNX-10 revealed the binding mode of the compound to the KR domain of FASN. Taken together, the study establishes compound QNX-10 to be a promising lead candidate for the development of anticancer therapeutics targeting the FASN enzyme.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDrug DesignEnzyme InhibitorsFatty Acid Synthase, Type IPiperazinesQuinoxalinesHumansApoptosisCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorMolecular Docking SimulationMolecular StructureStructure-Activity Relationship

Stichwörter der Autor:innen

Apoptosis InducerCancerCell Cycle ArrestFatty acid synthaseMD SimulationPhenylquinoxaline

Substanzen

Antineoplastic AgentsEnzyme InhibitorsFASN protein, humanFatty Acid Synthase, Type IPiperazinesQuinoxalines2-phenylquinoxaline

Autor:innen und Institutionen

  • Cancept Therapeutics Laboratory, Department of Pharmacy, Indira Gandhi National Tribal University, Lalpur, Amarkantak, Madhya Pradesh 484887, India; KL College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddes…
  • School of Biotechnology, KIIT Deemed to be University, Campus-11, Patia, Bhubaneswar, Odisha 751024, India.
  • UCIBIO-Applied Molecular Biosciences Unit, BioSIM-Departamento de Biomedicina, Faculdade de Medicina, Universidade do Porto, Porto 4200319, Portugal; Associate Laboratory i4HB-Institute for Health and Bioeconomy, Faculd…
  • Cancept Therapeutics Laboratory, Department of Pharmacy, Indira Gandhi National Tribal University, Lalpur, Amarkantak, Madhya Pradesh 484887, India. Electronic address: karthikeyanchandrabose@gmail.com.
  • Cancept Therapeutics Laboratory, Department of Pharmacy, Indira Gandhi National Tribal University, Lalpur, Amarkantak, Madhya Pradesh 484887, India. Electronic address: hari.nmoorthy@gmail.com.

Förderung

  • India Ministry of Science & Technology Department of Science and Technology
  • Indian Council of Medical Research

Zitieren

APA

Singh, S., Paul, S., Martins, F. G., Sousa, S. F., Kundu, C. N., Karthikeyan, C., & Moorthy, N. S. H. N. (2025). Design, synthesis and biological evaluation of 2-phenylquinoxaline carbonyl piperazine derivatives as novel FASN inhibitors with anticancer activity. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.108697

Vancouver

Singh S, Paul S, Martins FG, Sousa SF, Kundu CN, Karthikeyan C, et al. Design, synthesis and biological evaluation of 2-phenylquinoxaline carbonyl piperazine derivatives as novel FASN inhibitors with anticancer activity. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.108697

BibTeX
@article{Singh2025,
  author = {Singh, Shailendra and Paul, Subarno and Martins, Fábio G and Sousa, Sérgio F and Kundu, Chanakya N and Karthikeyan, Chandrabose and Moorthy, N S Hari Narayana},
  title = {Design, synthesis and biological evaluation of 2-phenylquinoxaline carbonyl piperazine derivatives as novel FASN inhibitors with anticancer activity},
  journal = {Bioorganic Chemistry},
  year = {2025},
  doi = {10.1016/j.bioorg.2025.108697}
}
Kostenlos starten →